Phosphosulindac Therapy for Central Sensitization Pain Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for pain associated with central sensitization, including neuropathic pain and peripheral neuropathies, are ineffective, particularly as NSAIDs fail to provide significant pain relief, and existing therapies often have adverse side effects.

Innovation Solution

Phosphosulindac (PS) is administered to directly target central sensitization by reducing neuronal signaling in the CNS, providing analgesic effects on pain generated at central sites of action, such as allodynia and hyperalgesia, through mechanisms independent of COX-1 and COX-2 inhibition.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If NSAIDs are used to treat pain associated with central sensitization, then anti-inflammatory effects are achieved, but pain relief is insufficient

Engineering Contradiction:

Improvepain relief effectivenessVSAvoidineffectiveness of conventional treatment

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the mechanism of action from COX-1/COX-2 inhibition (traditional NSAID mechanism) to P2X7 receptor antagonism. This parameter change in the molecular target allows the compound to effectively treat central sensitization pain that is resistant to conventional NSAIDs, while maintaining anti-inflammatory properties.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces an intermediary mechanism by blocking P2X7 receptors, which are activated by extracellular ATP during inflammation and pain. This intermediary approach prevents the downstream signaling that leads to central sensitization and neuronal hyperexcitability, providing pain relief where direct COX inhibition fails.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If existing therapies for neuropathic pain are administered, then some pain relief may be achieved, but adverse side effects occur

Engineering Contradiction:

Improvepain reliefVSAvoidadverse side effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the therapeutic parameter from traditional analgesic mechanisms to selective P2X7 receptor antagonism. This specificity allows for effective neuropathic pain treatment while avoiding the broad-spectrum side effects associated with conventional pain medications, as the action is targeted to a specific receptor involved in pain signaling.

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If conventional analgesics are used, then general pain relief is provided, but they fail to address central sensitization specifically

Engineering Contradiction:

Improvebroad pain treatment capabilityVSAvoidefficacy for central sensitization pain

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies local quality by targeting the specific pathophysiology of central sensitization through P2X7 receptor antagonism. Rather than providing general pain relief, the compound specifically addresses the neuronal hyperexcitability and central pain signaling mechanisms, making it adaptable to central sensitization conditions while maintaining broad applicability to various underlying causes.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20250345350A1Treating pain associated with central sensitization

Publication Date: 2025.11.13 MEDICON PHARMACEUTICALS INC

AI summary

The invention features methods of treating pain, for example pain associated with central sensitization, with phosphosulindac and compositions thereof.